MedTrace Logo

Bisphosphonates and Impaction Grafting in Hip Revision

NCT00658268 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2017-08-15

No results posted yet for this study

Summary

The primary focus of this study is to investigate whether increased bone density of the graft in revision arthroplasty of the hip can cause a decreased micromotion of the implant relative to the femur.

Conditions

  • Aseptic Loosening of the Hip Prosthesis

Interventions

DRUG

Clodronate

60 mg/ml, 10 ml, single dose mixed in bone graft at operation

DRUG

Placebo

10 ml, single dose mixed in bone graft at operation

Sponsors & Collaborators

  • Region Skane

    lead OTHER

Principal Investigators

  • Magnus Tagil, MD, PhD · Department of Orthopaedics, Lund University Hospital,Lund, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2017-08-01
Completion
2017-08-01

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00658268 on ClinicalTrials.gov